Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Publication Date: April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...iagnosi...

...y Diagnosed ER-positive, HER2-negative Breast...

Oncotype DX (21-gene recur...

...1.1If a patient has node-negative breast cancer...

...n 1.2In the group of patients in Recom...

...1.3In the group of patients in Rec...

...1.4If a patient is postmenopausal and has...

...ecommendation 1.5In the group of patien...

....6If a patient is premenopausal and has nod...

...on 1.7If a patient has node-positive brea...

...int (70-gene signatu...

...ndation 1.8If a patient is older than 50 and ha...

...ecommendation 1.9If a patient is 50 years of a...

....10If a patient has low clinical risk, regar...

...ion 1.11If a patient has node-positive b...

...ct (12-gene risk score)...

Recommendation 1.12If a patient is postmenopausa...

...mendation 1.13If a patient is premenopausal and...

...mendation 1.14If a patient has brea...

...gna (PAM50)...

...on 1.15If a patient is postmenopau...

...tion 1.16If a patient is premenopa...

...ion 1.17If a patient is postmenopaus...

...mendation 1.18If a patient has node-positiv...

Mammostrat

...insufficient evidence to recommend use of Ma...

Breast Cancer Index...

...patient has ER-positive, HER2-negative...

...patient has ER-positive, HER2-negative, no...

...i67

...commendation 1.19If a patient is postmeno...

...tion 1.20If a patient is postmenopausal and...

...ecommendation 1.21Despite the limitations...

...ohistochemistry 4 (IH...

....22If a patient has node-negative or...

uPA and PAI-...

...nt has ER-positive, HER2-negative (node...

...patient has HER2-positive breast cancer or...


...ended Endocrine Therapy For ER Recepto...

...otype DX, EndoPredict, Prosigna, Ki6...

...commendation 1.23If a patient has node-negative...

BC...

...1.24If a patient has node-negative or...

...tion 1.25If a patient has node-positive brea...

...ment Score post-5 Years (CTS5)...

...dation 1.26If a patient is postmenopau...


...itive Breast Cancer or TNBC...

...DX, EndoPredict, MammaPrint, BCI, Prosigna...

...ndation 1.27If a patient has HER2-po...


...rging Biomarkers

...or-Infiltrating Lymphocytes...

...1.28If a patient has node-negative...

...-L1 TestingĀ...

...ndation 1.29If a patient has node-n...

...rculating Tumor Cells (CTC...

...n 1.30If a patient has node-negative...

Circulating Tumor DNA...

...ation 1.31If a patient has node-negative or node-p...


...le 1. Breast Cancer Biomarkers to...


...e 1. Algorithm on Biomarkers to Guide D...


...Classification of Patients According to C...


...ASCO believes that cancer clinical trials...